NVO Novo Nordisk A/S
NVO Novo Nordisk A/S
Healthcare · Drug Manufacturers - General
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 bear converging
POC $38.14 · VWAP $45.97 · -15.5% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 related campaign
NVO Price Structure
Loading timeframes…
Peers
Every watchlist NVO belongs to, members best 30-day change first — NVO highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@peptide-economy
@biotech-scan
Reported EPS $6.18 versus analyst consensus of $4.98 (+24.0%).
full note →Against street estimates
How NVO's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about NVO from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 24 days ago · Sep 23
- Novo Nordisk A/S (NVO) Earnings Report: Key Numbers & Transcript Summary
- Novo Nordisk A/S (NVO) Stock Earnings Call Transcripts - Yahoo Finance
- Novo Nordisk Stock Price Today | NYSE: NVO Live - Investing.com
- Novo Nordisk and Orbis ink drug discovery deal (NVO:NYSE) | Seeking Alpha
- Novo Nordisk releases earnings and guidance - CNBC
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
NVO research tape
45 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.